From: A novel multiplex assay combining autoantibodies plus PSA has potential implications for classification of prostate cancer from non-malignant cases
Variables
Sensitivity
Specificity
False positive
Accuracy
AUC
PSA alone in all patients
52% (68/131)
79% (95/121)
21% (26/121)
65%
0.66
A+PSA in all patients
79% (103/131)
84% (102/121)
16% (19/121)
81%
0.91 P < 0.0001